ABPI and OBN collaborate for life sciences
UK pharma organisations, the Association of the British Pharmaceutical Industry (ABPI) and OBN, which represents emerging life sciences companies, are to work together for the benefit of members and the wider health economy.
To this end, they have signed a Memorandum of Understanding (MoU), which will facilitate new partnerships to help build a better public profile for biosciences. In practical terms, ABPI advocacy approaches may now include the interests of OBN members, as well as training opportunities and events, particularly in the R&D arena.
Stephen Whitehead, CEO of the ABPI said the agreement would provide the opportunity to deliver some innovative joint activities. "The health and research ecosystem is changing and partnership at all stages of the medicines development process is often key to success. This MoU presents an opportunity for us and our combined membership to work collaboratively in this way," he explained.
Jon Rees, CEO of OBN said: "OBN is keen to partner non-exclusively with other leading associations to further our members' interests. Historically we have used our high quality networking events for innovative R&D companies, investors and large pharma as a means to understand and serve members' interests. As our membership has grown substantially, now over 350 companies, we have expanded our activities and engage with government over issues that are impacting the growth of our member companies. We welcome the opportunity to work with the ABPI within its smaller companies' environment initiative and beyond. By combining the interests of innovative R&D and large pharma companies, our collaboration adds weight to the voice of emerging companies with key stakeholders."
ABPI members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline.
Links
